Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.8300
-0.0035 (-0.42%)
At close: Aug 13, 2025, 4:00 PM
0.8300
0.00 (0.00%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2024. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
$87,989
Profits / Employee
-$1,627,256
Market Cap
16.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LEXX News
- 5 minutes ago - Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - TheNewswire
- 5 minutes ago - Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - Accesswire
- 8 days ago - GLP-1 "Arms Race" Broadens to Include Dozens of Companies - Accesswire
- 17 days ago - Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study - TheNewswire
- 17 days ago - Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study - Accesswire
- 22 days ago - Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry - Accesswire
- 7 weeks ago - Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide - TheNewswire
- 2 months ago - Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule - TheNewswire